Clinical Trial Update: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching to fixed-dose combination B/F/TAF in virologically suppressed adults with HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Bictegravir/Emtricitabine/Tenofovir Alafenamide (Bictegravir/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1-infection | Phase 3 | Status: COMPLETED | Results posted: 2019-11-20